glp-1 drug tirzepatide Drugs May Lower CV Risk in TAVI Patients With Diabetes or Obesity FDA says shortage of GLP-1

Its approved for people with obesity (a body mass index [BMI] of 30 or more) or overweight (a BMI of 27 or more) with at least 1 weight-related health condition such as high cholesterol, high blood pressure, or type 2 diabetes

Final Thoughts Starting GLP-1 treatment is an exciting step toward better health

Monitoring blood sugar levels regularly can show how well the medication is working

however, members may still be on longer if they determine, with their clinician, they need additional support

*El equipo de periodistas y expertos de ConsumoClaro recomienda de forma rigurosa e independiente productos y servicios para nuestros lectores